Loading...
Market
First Market Approval for GSK Asthma Drug by End of 2025
5
Resolution / Starting Odds
UK • 25%
USA • 25%
EU • 25%
Canada • 25%
Official regulatory announcements from respective regions
Story
GSK's Experimental Asthma Drug Shows Promise in Late-Stage Trials, Potential £3 Billion Sales
May 21, 2024, 07:01 AM
An experimental drug from GlaxoSmithKline (GSK) has shown promising results in reducing severe asthma attacks in late-stage trials. The British pharmaceutical company announced on Tuesday that the drug met its primary goal of reducing asthma attacks over a 52-week period in a key trial. The success of these trials paves the way for a treatment that GSK believes could exceed £3 billion in sales, potentially making it a blockbuster product.
View original story
Similar markets
Less than 10 countries • 25%
10-20 countries • 25%
20-30 countries • 25%
More than 30 countries • 25%
Below £500 million • 25%
£500 million to £1 billion • 25%
£1 billion to £2 billion • 25%
Above £2 billion • 25%
Increase • 33%
No significant change • 33%
Decrease • 33%
Top 1 • 25%
Top 2 • 25%
Top 3 • 25%
Top 4+ • 25%
